Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

giredestrant (GDC-9545)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Roche

Drug class:

Estrogen receptor antagonist, Selective estrogen receptor degrader

Related drugs:

ER mutation	HER2 Negative Breast Cancer	ER mutation	HER2 Negative Breast Cancer	GDC-9545 Sensitive: C2 – Inclusion Criteria GDC-9545 Sensitive : C2	GDC-9545 Sensitive: C2 – Inclusion Criteria GDC-9545 Sensitive : C2
ER positive	HER2 Negative Breast Cancer	ER positive	HER2 Negative Breast Cancer	GDC-9545 Sensitive: C2 – Inclusion Criteria GDC-9545 Sensitive : C2	GDC-9545 Sensitive: C2 – Inclusion Criteria GDC-9545 Sensitive : C2
ER positive + ESR1 mutation	HER2 Negative Breast Cancer	ER positive + ESR1 mutation	HER2 Negative Breast Cancer	inavolisib + GDC-9545 Sensitive: C3 – Early Trials inavolisib + GDC-9545 Sensitive : C3	inavolisib + GDC-9545 Sensitive: C3 – Early Trials inavolisib + GDC-9545 Sensitive : C3
ER Y537S	Estrogen Receptor Positive Breast Cancer	ER Y537S	Estrogen Receptor Positive Breast Cancer	GDC-9545 Sensitive: D – Preclinical GDC-9545 Sensitive : D	GDC-9545 Sensitive: D – Preclinical GDC-9545 Sensitive : D